Please login to the form below
smoking cessation
This page shows the latest smoking cessation news and features for those working in and with pharma, biotech and healthcare.
Alex Butler and Matt Baker launch Foundry3
a range of digital health start-ups focused on areas such as fertility, smoking cessation and GPs’diagnostic decisions.
Latest news
-
Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects
EAGLES trial of 8, 000 patients backs the smoking cessation drugs' safety. ... A much-anticipated clinical trial of two drugs used as smoking cessation therapies has concluded that they do not cause neuropsychiatric side effects such as suicidal ideation.
-
Digital technology and patient support
Likewise, smoking cessation app Smartquit has been so successful that the National Cancer Institute has awarded a $3.1m grant to conduct a clinical trial to test its effectiveness.
-
Study clears Pfizer’s Champix of serious risks
Study clears Pfizer’ s Champix of serious risks. Smoking-cessation drug 'does not increase risk' of depression or heart attacks. ... Champix, marketed as Chantix in the US, achieved global sales of $647m in 2014 making it one of the highest-selling
-
FDA panel backs Sprout Pharma's 'female Viagra'
REMS are already in place for other 'lifestyle' drugs such as Vivus' Qsymia (phentermine/topiramate) for obesity and Pfizer's smoking cessation therapy Chantix (varenicline).
-
Pfizer collaborates with vloggers on YouTube smoking cessation campaign
Pfizer collaborates with vloggers on YouTube smoking cessation campaign. Will work with film makers such as Dan Bull, Steven Bridges and Cherry Wallis. ... Pfizer is collaborating with six YouTube film makers on a two-month UK smoking cessation campaign.
More from news
Approximately 4 fully matching, plus 93 partially matching documents found.
Latest Intelligence
-
If a nudge doesn’t last forever, how do we ensure sustained behaviour change?
groups. The same is true in smoking cessation. In a systematic review of the effectiveness of nudges based on incentives and competition (including investing their own money), only one of 19 ... In order to achieve sustained behaviour change in relation
-
Pharma deals in June 2015
Acquisition - company. 200. Eolas Therapeutics/ AstraZeneca. Orexin-1 Receptor Antagonist (EORA) programme for smoking cessation and other indications (preclinical).
-
Community pharmacy and OTC healthcare
Pharmacists' wellness and prevention role means intervening when people are still well and many provide services such as weight management, smoking cessation and cholesterol and blood pressure monitoring.
-
Pharma deals during April 2014
Smoking cessation: Nicorette and Nicoderm (GSK), Nicotinell (Novartis). • Cold-and-flu: Theraflu and Triaminic (Novartis), Coldrex (GSK). •
-
Denmark: rising pharma spend amid healthcare cost-containment
Another feature distinguishes the healthcare landscape in Denmark: health indicators show that Denmark lags behind other Nordic countries due to risk factors such as alcohol intake, smoking and obesity. ... promote smoking cessation; prohibition of the
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
ABPI names NHS partnership manager
Tugnet managed a specialist healthcare development team at Nicoventures, which markets nicotine products for use in smoking cessation.
-
Zeno Group appoints new UK healthcare director
During this time, she has gain experience covering therapy areas including allergy, cardiology, dental, diabetes, nutrition, skincare, smoking cessation, urology, vaccines, weight loss and wound care.
-
Ogilvy Brussels names new associate director
During her time with the group, she supported Pfizer with the design and implementation of the integrated 'Siga red' campaign, for smoking cessation, and she managed the 'Lights out' campaign for
-
Kane & Finkel announces new European director
In addition, as director of communications for the UK's Health Education Authority, he also developed public health campaigns for AIDS, smoking cessation, childhood immunisation and heart disease.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Is obesity the new smoking?
Is obesity the new smoking? Is obesity the new smoking? The healthcare PR team at Say communications analyses the question posed by NHS Chief executive Simon Stevens. ... He goes on to describes obesity as ‘ the new smoking’ – the biggest cause of
-
90TEN’s PR division boosted with hires from Ketchum and Liberation Unlimited
O’ Connor moves to 90TEN following three years at Ketchum where she worked on both global and UK accounts across immunology, smoking cessation, men’ s health and third sector clients.
-
Health behaviour change: Getting patients to accept treatment
knowing their attitudes, fears, hopes and desires. Smoking cessation, for example, may be ‘ giving up’ to one but ‘ taking on’ to another, so the job of doctors, HCPs and pharma is
-
Doctors Embracing Digital Technology – But Are Reluctant To Prescribe Apps And Wearables For Patients
Smoking Cessation (49%), and Compliance (45%). ·
-
England may be losers, but is your health a winner?
England may be losers, but is your health a winner? England is out of the 2015 rugby world cup, but is your health a winner? We lost; we’ re out of the world cup. It’ s a predictable state of affairs for an English sports fan. But is there a
More from PMHub
Approximately 2 fully matching, plus 6 partially matching documents found.
Featured jobs
- Sudler London - Senior Medical Writer
-
Competitive
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Systematic Review Lead- London
-
Negotiable
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
Negotiable
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Medical Writer
-
Salary is DOE
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Healthcare PR Senior Account Manager
-
Salary TBC
Subscribe to our email news alerts
- Moving annual total (MAT)
- Key success factor (KSF)
- AZ prepares to file COPD triple, taking on rival GSK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Teva wins FDA OK for crucial migraine drug
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Page & Page
Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
